We have located links that may give you full text access.
Clinical Trial
Journal Article
Periurethral fat injection in the treatment of recurrent genuine stress incontinence.
Journal of Urology 1998 Februrary
PURPOSE: We evaluated the efficacy, safety and mechanism of periurethral fat injection in the treatment of recurrent genuine stress incontinence.
MATERIALS AND METHODS: Periurethral fat injections were performed in 26 patients for the treatment of recurrent genuine stress incontinence. A complete urogynecological study, including a 1-hour pad test, urodynamic studies and chain urethrocystography were done in each case and were repeated at least 3 months after operation. Each patient was followed for at least 12 months.
RESULTS: Of 26 patients 13 (50%) were dry after operation and 4 (15.4%) showed improvement and were satisfied with the results of the operation, giving a total success rate of 65.4%. There were 6 cases of immediate postoperative minor complications (23%). Average volume of injected fat was 14.8 +/- 4.8 cc, which did not affect the success rate. Preoperative and postoperative chain urethrocystographic values for bladder neck descent in reference to the pubosacral tip line showed no statistical difference between successfully and unsuccessfully treated groups. Urodynamic studies in all cases showed no differences relating to operation. However, minimal urethral resistance increased from 0.122 +/- 0.061 to 0.205 +/- 0.134 (p = 0.023) in the treatment success group. This change was not demonstrated in the treatment failure group.
CONCLUSIONS: Periurethral fat injection for the treatment of recurrent genuine stress incontinence is a simple technique that works by the increment of urethral resistance. It has an acceptable success rate without financial outlay for the injected material.
MATERIALS AND METHODS: Periurethral fat injections were performed in 26 patients for the treatment of recurrent genuine stress incontinence. A complete urogynecological study, including a 1-hour pad test, urodynamic studies and chain urethrocystography were done in each case and were repeated at least 3 months after operation. Each patient was followed for at least 12 months.
RESULTS: Of 26 patients 13 (50%) were dry after operation and 4 (15.4%) showed improvement and were satisfied with the results of the operation, giving a total success rate of 65.4%. There were 6 cases of immediate postoperative minor complications (23%). Average volume of injected fat was 14.8 +/- 4.8 cc, which did not affect the success rate. Preoperative and postoperative chain urethrocystographic values for bladder neck descent in reference to the pubosacral tip line showed no statistical difference between successfully and unsuccessfully treated groups. Urodynamic studies in all cases showed no differences relating to operation. However, minimal urethral resistance increased from 0.122 +/- 0.061 to 0.205 +/- 0.134 (p = 0.023) in the treatment success group. This change was not demonstrated in the treatment failure group.
CONCLUSIONS: Periurethral fat injection for the treatment of recurrent genuine stress incontinence is a simple technique that works by the increment of urethral resistance. It has an acceptable success rate without financial outlay for the injected material.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app